Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP

Oncogene

Volumn 24, Issue 46, 2005, Pages 6877-6889

  Eun, Hee Kim ^a   Hee, Sue Kim ^a   Kim, Seung U ^a,b   Eun, Joo Noh ^b   Lee, Jong Soo ^b,c   Choi, Kyeong Sook ^a  

^a Ajou University School of Medicine   (South Korea)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c National Cancer Center   (South Korea)

Author keywords

Apoptosis; Glioma; Sodium butyrate; TRAIL

Indexed keywords

BUTYRIC ACID; CASPASE INHIBITOR; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; PROCASPASE 3; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; RECOMBINANT PROTEIN; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; ASTROCYTE; CELL ACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASTROCYTES; BASE SEQUENCE; BUTYRIC ACID; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; DNA PRIMERS; DOWN-REGULATION; ENZYME INHIBITORS; GLIOMA; HISTONE DEACETYLASES; HUMANS; MEMBRANE GLYCOPROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 27144451394     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1208851     Document Type: Article

References (60)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH. (1999). J. Clin. Invest., 104, 155-162.
2. Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A and Remiszewski S. (2004). Cancer Res., 64, 689-695.
3. Bernhard D, Ausserlechner MJ, Tonko M, Loffler M, Hartmann BL, Csordas A and Kofler R. (1999). FASEB J., 13, 1991-2001.
4. Boatright KM and Salvesen GS. (2003). Curr. Opin. Cell Biol., 15, 725-731.
5. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T and Lees JA. (1999). Proc. Natl. Acad. Sci. USA, 96, 1002-1007.
6. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS. (2002). J. Clin. Oncol., 20, 1063-1068.
7. Chen JS, Faller DV and Spanjaard RA. (2003). Curr. Cancer Drug Targets, 3, 219-236.
8. Chopin V, Slomianny C, Hondermarck H and Le Bourhis X. (2004). Exp. Cell. Res., 298, 560-573.
9. Deveraux QL and Reed JC. (1999). Genes Dev., 13, 239-252.
10. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS and Reed JC. (1999). EMBO J., 18, 5241-5251.
11. Earnshaw WC, Martins LM and Kaufmann SH. (1999). Annu. Rev. Biochem., 68, 383-424.
12. Gui CY, Ngo L, Xu WS, Richon VM and Marks PA. (2004). Proc. Natl. Acad. Sci. USA, 101, 1241-1246.
13. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P and Bhalla K. (2004). Cancer Res., 64, 2580-2589.
14. Han Z, Hendrickson EA, Bremner TA and Wyche JH. (1997). J. Biol. Chem., 272, 13432-13436.
15. Heerdt BG, Houston MA and Augenlicht LH. (1994). Cancer Res., 54, 3288-3293.
16. Heerdt BG, Houston MA and Augenlicht LH. (1997). Cell Growth Differ., 8, 523-532.
17. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH and Evers BM. (2001). Surgery, 130, 265-272.
18. Huang DC, Cory S and Strasser A. (1997). Oncogene, 14, 405-414.
19. Ito N, Sawa H, Nagane M, Noguchi A, Hara M and Saito I. (2001). Neurosurgery, 49, 430-436.
20. Kamitani H, Taniura S, Watanabe K, Sakamoto M, Watanabe T and Eling T. (2002). Neuro-oncology, 4, 95-101.
21. Katula KS, Wright KL, Paul H, Surman DR, Nuckolls FJ, Smith JW, Ting JP, Yates J and Cogswell JP. (1997). Cell Growth Differ., 8, 811-820.
22. Kim EH, Kim SU, Shin DY and Choi KS. (2004b). Oncogene, 23, 446-456.
23. Kim SU, Moretto G, Lee V and Yu RK. (1986). J. Neurosci. Res., 15, 303-321.
24. Kim SU. (1985). J. Neuroimmunol., 8, 255-282.
25. Kim YH, Park JW, Lee JY and Kwon TK. (2004a). Carcinogenesis, 25, 1813-1820.
26. Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R, Kastan MB, Lazebnik YA and Hardwick JM. (1999). J. Biol. Chem., 274, 21155-21161.
27. Knight MJ, Riffkin CD, Muscat AM, Ashley DM and Hawkins CJ. (2001). Oncogene, 20, 5789-5798.
28. Kobayashi K, Hatano M, Otaki M, Ogasawara T and Tokuhisa T. (1999). Proc. Natl. Acad. Sci. USA, 96, 1457-1462.
29. Kramer A, Carstens CP, Wasserman WW and Fahl WE. (1997). Cancer Res., 57, 5117-5121.
30. Kruh J. (1982). Mol. Cell Biochem., 42, 65-82.
31. Legler JM, Ries LA, Smith MA, Warren JL, Heinmann EF, Kaplan RS and Linnet MS. (1999). J. Natl. Cancer Inst., 91, 1382-1390.
32. Lipinski CA, Tran NL, Bay C, Kloss J, McDonough WS, Beaudry C, Berens ME and Loftus JC. (2003). Mol. Cancer Res., 1, 323-332.
33. Marks PA, Richon VM, Breslow R and Rifkind RA. (2001). Curr. Opin. Oncol., 13, 477-483.
34. Misra A, Chattopadhyay P, Dinda AK, Sarkar C, Mahapatra AK, Hasnain SE and Sinha S. (2000). J. Neurooncol., 48, 1-12.
35. Nair AR, Boersma LJ, Schiltz L, Chaudhry MA and Muschel RJ. (2001). Cancer Lett., 166, 55-64.
36. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T. (2004). Oncogene, 23, 6261-6271.
37. Neuzil J, Swettenham E and Gellert N. (2004). Biochem. Biophys. Res. Commun., 314, 186-191.
38. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin TT and Miller DK. (1995). Nature, 376, 37-43.
39. Nomura T, Mimata H, Takeuchi Y, Yamamoto H, Miyamoto E and Nomura Y. (2003). Urol. Res., 31, 37-44.
40. Pellizzaro C, Coradini D, Daniotti A, Abolafio G and Daidone MG. (2001). Int. J. Cancer, 91, 654-657.
41. Piekarz R and Bates S. (2004). Curr. Pharm. Des., 10, 2289-2298.
42. Rokudai S, Fujita N, Hashimoto Y and Tsuruo T. (2000). J. Cell Physiol., 182, 290-296.
43. Rosato RR, Almenara JA, Dai Y and Grant S. (2003). Mol. Cancer Ther., 2, 1273-1284.
44. Sawa H, Murakami H, Ohshima Y, Murakami M, Yamazaki I, Tamura Y, Mima T, Satone A, Ide W, Hashimoto I and Kamada H. (2002). Brain Tumor Pathol., 19, 77-81.
45. Seol DW, Li J, Seol MH, Park SY, Talanian RV and Billiar TR. (2001). Cancer Res., 61, 1138-1143.
46. Shankar S and Srivastava RK. (2004). Drug Resist. Update, 7, 139-156.
47. Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP and Blottiere HM. (2000). Gut, 46, 507-514.
48. Suliman A, Lam A, Datta R and Srivastava RK. (2001). Oncogene, 20, 2122-2133.
49. Sun XM, Bratton SB, Butterworth M, MacFarlane M and Cohen GM. (2002). J. Biol Chem., 277, 11345-11351.
50. Suzuki Y, Nakabayashi Y and Takahashi R. (2001). Proc. Natl. Acad. Sci. USA, 98, 8662-8667.
51. Tewari M, Beidler DR and Dixit VM. (1995). J. Biol. Chem., 270, 18738-18741.
52. Vigushin DM and Coombes RC. (2002). Anticancer Drugs, 13, 1-13.
53. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I and Coombes RC. (2001). Clin. Cancer Res., 7, 971-976.
54. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH. (1999). Nat. Med., 5, 157-163.
55. Wang S and El-Deiry WS. (2003). Oncogene, 22, 8628-8633.
56. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA and Goodwin RG. (1995). Immunity, 3, 673-682.
57. Yokota T, Matuszaki Y, Miyazawa K, Zindy F, Roussel MF and Sakai T. (2004). Oncogene, 23, 5340-5349.
58. Zaffaroni N and Daidone MG. (2002). Drug Resist. Update, 5, 65-72.
59. Zhang XD, Gillespie SK, Borrow JM and Hersey P. (2003). Biochem. Pharmacol., 66, 1537-1545.
60. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM and Salvesen GS. (1997). J. Biol. Chem., 272, 7797-8000.